Palvella Therapeutics, Inc. $PVLA Shares Purchased by The Manufacturers Life Insurance Company

Key Points

• Institutional ownership increased significantly: The Manufacturers Life Insurance Company raised its Palvella Therapeutics stake by 688.9% to 17,907 shares, while several other major funds also added positions. Institutions and hedge funds now own 40.11% of the stock.
• PVLA shares are near a 52-week high but remain unprofitable: Shares recently traded at $157.77, while the company reported a quarterly loss of $1.52 per share, missing estimates of a $1.17 loss.
• The outlook depends heavily on QTORIN approval: Analysts maintain a consensus “Buy” rating and average price target of $209.14, but valuation concerns and continued projected losses make regulatory approval and successful commercialization critical to further upside.

The Manufacturers Life Insurance Company increased its holdings in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report) by 688.9% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 17,907 shares of the company's stock after buying an additional 15,637 shares during the period. The Manufacturers Life Insurance Company owned about 0.12% of Palvella Therapeutics worth $2,232,000 at the end of the most recent quarter.

A number of other hedge funds also recently added to or reduced their stakes in the business. Summit Partners Public Asset Management LLC boosted its position in Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company's stock valued at $40,761,000 after buying an additional 354,525 shares during the period. Vanguard Group Inc. boosted its holdings in Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company's stock valued at $31,010,000 after purchasing an additional 330,847 shares during the period. State Street Corp grew its stake in Palvella Therapeutics by 206.3% during the 4th quarter. State Street Corp now owns 420,462 shares of the company's stock worth $44,010,000 after purchasing an additional 283,211 shares in the last quarter. Jennison Associates LLC grew its stake in Palvella Therapeutics by 262.4% during the 4th quarter. Jennison Associates LLC now owns 387,483 shares of the company's stock worth $40,558,000 after purchasing an additional 280,573 shares in the last quarter. Finally, First Light Asset Management LLC increased its holdings in Palvella Therapeutics by 38.3% during the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company's stock worth $122,251,000 after purchasing an additional 271,617 shares during the period. 40.11% of the stock is currently owned by institutional investors and hedge funds.

Palvella Therapeutics Trading Up 1.8%

Shares of NASDAQ:PVLA opened at $157.77 on Friday. The firm has a 50 day simple moving average of $133.76 and a 200-day simple moving average of $120.02. Palvella Therapeutics, Inc. has a twelve month low of $38.95 and a twelve month high of $161.38. The company has a market capitalization of $2.27 billion, a PE ratio of -32.66 and a beta of -0.17.

Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). As a group, equities research analysts predict that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $110.73, for a total transaction of $476,360.46. Following the sale, the chief operating officer owned 2,154 shares in the company, valued at approximately $238,512.42. The trade was a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company's stock.

Palvella Therapeutics News Summary

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Investor focus is on the potential approval of QTORIN, Palvella’s lead product candidate. Approval could provide a path to commercialization and future revenue growth, supporting the bullish outlook ahead of the regulatory decision. Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $270 price target, implying substantial upside from recent trading levels. Its projections anticipate a transition from losses to positive earnings beginning in 2029, with EPS forecast at $6.18 in 2029 and $19.10 in 2030.
• Neutral Sentiment: The latest analysis questions whether PVLA is already fully valued ahead of the QTORIN approval decision. With the stock near its 52-week high and a market capitalization of approximately $2.27 billion, further gains may depend heavily on a favorable regulatory outcome and successful commercialization.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts across multiple periods: 2026 to a loss of $6.79 per share, 2027 to a loss of $7.43, and 2028 to a loss of $0.83. The firm also lowered its 2029 forecast from $7.81 to $6.18 and its 2030 forecast from $21.72 to $19.10.
• Negative Sentiment: Near-term quarterly estimates were also cut, with projected losses of $1.98 per share for the third quarter of 2026 and $2.05 for the fourth quarter. The revisions reinforce that Palvella remains an unprofitable biotechnology company and may require continued funding before reaching profitability. Palvella Therapeutics analyst estimates

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Truist Financial set a $207.00 target price on Palvella Therapeutics in a report on Wednesday. HC Wainwright restated a "buy" rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a report on Wednesday. Finally, Stephens reaffirmed an "overweight" rating and set a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $209.14.

About Palvella Therapeutics

Palvella Therapeutics, Inc NASDAQ: PVLA is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella's pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Want to see what other hedge funds are holding PVLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palvella Therapeutics, Inc. (NASDAQ:PVLA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source